NASDAQ · Biotechnology · USD

First Tracks Biotherapeutics, Inc. (TRAX) Stock Analysis

First Tracks Biotherapeutics, Inc. (TRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TRAX

$42.77

+$1.52 (+3.68%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRAX with… →

TRAX Key Statistics

As of Oct 21, 2026

Trading

Open: $41.20
Previous Close: $41.25
Day's Range: 40.00–42.89
52-Week Range: 14.72–49.91
Volume: 711.43K

Valuation

Market Cap: $1.53B
P/E Ratio: unprofitable
EPS (ttm): −4.71

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$163.71M
Shares Outstanding: 35.73M

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 859.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

First Tracks Biotherapeutics, Inc. (TRAX) has a market capitalization of $1.53B.

In fiscal 2024, TRAX reported revenue of $0.00.

TRAX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2024	$0.00	−$163.71M	—
2023	$0.00	−$106.15M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2024	$0.00	—	−$181.10M	−$163.71M	—
2023	$0.00	—	−$118.46M	−$106.15M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2024.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

First Tracks Biotherapeutics, Inc. (TRAX) is capitalised at $1.53B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 104.

The 52-week range on file runs from $14.72 to $49.91. TRAX last closed at $42.77 on October 21, 2026. That is +$1.52 (+3.68%) against the previous close. The latest close sits 190.56% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $0.00. The same year closed with a net loss of $163.71M. Earnings per share on a trailing basis come to −4.71.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on April 6, 2026, and the total return since then is +125.11%.

Growth & Income

The record shows no dividend for TRAX.

So far in 2026 the total return is +125.11%.

Peer Comparison

First Tracks Biotherapeutics, Inc. (TRAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
First Tracks Biotherapeutics, Inc.	TRAX	$1.53B	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. First Tracks Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Visit website →

First Tracks Biotherapeutics, Inc. (TRAX) Stock Analysis

Price History

TRAX Key Statistics

TRAX Revenue and Earnings by Fiscal Year

Recent News

Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90

First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60

Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70

7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data

First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data

Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70

First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results

First Tracks: ANB033 Delivers, But Cohort 2 Must Follow Through

First Tracks climbs on ‘impressive’ celiac study data

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results

Why Is First Tracks Biotherapeutics Stock Soaring Monday?

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50